Switch to:
Also traded in: Germany, Mexico, Switzerland, UK

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt 1.10
BAX's Cash-to-Debt is ranked lower than
53% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.55 vs. BAX: 1.10 )
Ranked among companies with meaningful Cash-to-Debt only.
BAX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01  Med: 0.24 Max: N/A
Current: 1.1
Equity-to-Asset 0.54
BAX's Equity-to-Asset is ranked lower than
59% of the 184 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.61 vs. BAX: 0.54 )
Ranked among companies with meaningful Equity-to-Asset only.
BAX' s Equity-to-Asset Range Over the Past 10 Years
Min: 0.22  Med: 0.37 Max: 0.56
Current: 0.54
0.22
0.56
Interest Coverage 14.21
BAX's Interest Coverage is ranked lower than
70% of the 135 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 40.83 vs. BAX: 14.21 )
Ranked among companies with meaningful Interest Coverage only.
BAX' s Interest Coverage Range Over the Past 10 Years
Min: 3.08  Med: 17.4 Max: 32.02
Current: 14.21
3.08
32.02
Piotroski F-Score: 6
Altman Z-Score: 4.94
Beneish M-Score: -2.81
WACC vs ROIC
6.43%
11.53%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 11.19
BAX's Operating Margin % is ranked higher than
59% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.15 vs. BAX: 11.19 )
Ranked among companies with meaningful Operating Margin % only.
BAX' s Operating Margin % Range Over the Past 10 Years
Min: 4.5  Med: 17.94 Max: 22.9
Current: 11.19
4.5
22.9
Net Margin % 8.85
BAX's Net Margin % is ranked higher than
86% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.28 vs. BAX: 8.85 )
Ranked among companies with meaningful Net Margin % only.
BAX' s Net Margin % Range Over the Past 10 Years
Min: 8.85  Med: 16.5 Max: 48.85
Current: 8.85
8.85
48.85
ROE % 10.50
BAX's ROE % is ranked higher than
89% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 6.37 vs. BAX: 10.50 )
Ranked among companies with meaningful ROE % only.
BAX' s ROE % Range Over the Past 10 Years
Min: 10.5  Med: 30.38 Max: 57.95
Current: 10.5
10.5
57.95
ROA % 5.69
BAX's ROA % is ranked higher than
83% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.13 vs. BAX: 5.69 )
Ranked among companies with meaningful ROA % only.
BAX' s ROA % Range Over the Past 10 Years
Min: 4.11  Med: 11.59 Max: 27.2
Current: 5.69
4.11
27.2
ROC (Joel Greenblatt) % 19.90
BAX's ROC (Joel Greenblatt) % is ranked higher than
79% of the 190 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 11.96 vs. BAX: 19.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
BAX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: 5.65  Med: 39.84 Max: 91.88
Current: 19.9
5.65
91.88
3-Year Revenue Growth Rate 2.50
BAX's 3-Year Revenue Growth Rate is ranked lower than
56% of the 156 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.80 vs. BAX: 2.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
BAX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -17.6  Med: 2.8 Max: 17.3
Current: 2.5
-17.6
17.3
3-Year EBITDA Growth Rate 71.00
BAX's 3-Year EBITDA Growth Rate is ranked higher than
93% of the 130 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.80 vs. BAX: 71.00 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
BAX' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: -28.3  Med: 2.9 Max: 71
Current: 71
-28.3
71
3-Year EPS without NRI Growth Rate 151.00
BAX's 3-Year EPS without NRI Growth Rate is ranked higher than
97% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.20 vs. BAX: 151.00 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
BAX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -44  Med: 7.1 Max: 169.6
Current: 151
-44
169.6
GuruFocus has detected 9 Warning Signs with Baxter International Inc $BAX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» BAX's 30-Y Financials

Financials (Next Earnings Date: 2017-10-25 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q3 2016

BAX Guru Trades in Q3 2016

Steven Cohen 227,300 sh (+6213.89%)
First Eagle Investment 2,635,577 sh (+23.75%)
Paul Tudor Jones 33,174 sh (+20.81%)
John Hussman 200,000 sh (+14.29%)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Murray Stahl 14,122 sh (unchged)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Leucadia National Sold Out
Charles Brandes Sold Out
Jeremy Grantham Sold Out
Mario Gabelli 123,500 sh (-1.28%)
Keeley Asset Management Corp 57,410 sh (-2.05%)
Mairs and Power 1,903,688 sh (-2.30%)
Lee Ainslie 67,360 sh (-8.60%)
Tweedy Browne 2,157,391 sh (-9.87%)
George Soros 254,327 sh (-10.55%)
Joel Greenblatt 638,063 sh (-24.86%)
Vanguard Health Care Fund 4,902,940 sh (-30.49%)
Richard Pzena 1,061,577 sh (-65.93%)
Jim Simons 158,000 sh (-72.91%)
» More
Q4 2016

BAX Guru Trades in Q4 2016

Bill Nygren 4,600,000 sh (New)
Joel Greenblatt 1,271,879 sh (+99.33%)
Lee Ainslie 71,400 sh (+6.00%)
John Hussman 202,300 sh (+1.15%)
Tom Gayner 22,000 sh (unchged)
Daniel Loeb 51,901,767 sh (unchged)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Steven Cohen Sold Out
Tweedy Browne 2,150,819 sh (-0.30%)
Paul Tudor Jones 32,911 sh (-0.79%)
Murray Stahl 13,922 sh (-1.42%)
Mario Gabelli 120,900 sh (-2.11%)
Mairs and Power 1,752,525 sh (-7.94%)
George Soros 184,327 sh (-27.52%)
Vanguard Health Care Fund 3,094,340 sh (-36.89%)
Jim Simons 64,100 sh (-59.43%)
Keeley Asset Management Corp 21,474 sh (-62.60%)
Richard Pzena 225,790 sh (-78.73%)
First Eagle Investment 1,100 sh (-99.96%)
» More
Q1 2017

BAX Guru Trades in Q1 2017

Jeremy Grantham 74,400 sh (New)
Steven Cohen 633,448 sh (New)
Caxton Associates 10,900 sh (New)
Jim Simons 1,897,115 sh (+2859.62%)
Bill Nygren 5,300,000 sh (+15.22%)
Vanguard Health Care Fund 3,094,340 sh (unchged)
First Eagle Investment 1,100 sh (unchged)
Tom Gayner 22,000 sh (unchged)
Tweedy Browne Global Value 1,055,212 sh (unchged)
George Soros Sold Out
Richard Pzena Sold Out
Murray Stahl 13,822 sh (-0.72%)
Mario Gabelli 119,600 sh (-1.08%)
Mairs and Power 1,631,800 sh (-6.89%)
Daniel Loeb 46,000,000 sh (-11.37%)
Joel Greenblatt 1,017,461 sh (-20.00%)
Paul Tudor Jones 25,876 sh (-21.38%)
Lee Ainslie 55,790 sh (-21.86%)
Tweedy Browne 1,559,436 sh (-27.50%)
John Hussman 102,300 sh (-49.43%)
» More
Q2 2017

BAX Guru Trades in Q2 2017

Robert Olstein 66,000 sh (New)
Dodge & Cox 3,382 sh (New)
Vanguard Health Care Fund 5,424,086 sh (+75.29%)
Jeremy Grantham 103,000 sh (+38.44%)
Jim Simons 1,978,413 sh (+4.29%)
Tweedy Browne Global Value 1,055,212 sh (unchged)
Tom Gayner 22,000 sh (unchged)
First Eagle Investment 1,100 sh (unchged)
Paul Tudor Jones Sold Out
Steven Cohen Sold Out
Mario Gabelli 119,300 sh (-0.25%)
Caxton Associates 10,800 sh (-0.92%)
Tweedy Browne 1,535,525 sh (-1.53%)
Murray Stahl 13,372 sh (-3.26%)
Mairs and Power 1,471,022 sh (-9.85%)
Daniel Loeb 41,000,000 sh (-10.87%)
Lee Ainslie 39,730 sh (-28.79%)
John Hussman 50,000 sh (-51.12%)
Joel Greenblatt 270,869 sh (-73.38%)
» More
» Details

Insider Trades

Latest Guru Trades with BAX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Vanguard Health Care Fund 2017-06-30 Add 75.29%0.3%$51.86 - $61.38 $ 60.827%5,424,086
Tweedy Browne 2017-06-30 Reduce -1.53%0.04%$51.86 - $61.38 $ 60.827%1,535,525
Joel Greenblatt 2017-06-30 Reduce -73.38%0.49%$51.86 - $61.38 $ 60.827%270,869
Mario Gabelli 2017-06-30 Reduce -0.25%$51.86 - $61.38 $ 60.827%119,300
Robert Olstein 2017-06-30 New Buy0.51%$51.86 - $61.38 $ 60.827%66,000
Dodge & Cox 2017-06-30 New Buy$51.86 - $61.38 $ 60.827%3,382
Bill Nygren 2017-03-31 Add 15.22%0.22%$44.44 - $52.3 $ 60.8224%5,300,000
Tweedy Browne 2017-03-31 Reduce -27.50%0.82%$44.44 - $52.3 $ 60.8224%1,559,436
Joel Greenblatt 2017-03-31 Reduce -20.00%0.15%$44.44 - $52.3 $ 60.8224%1,017,461
Mario Gabelli 2017-03-31 Reduce -1.08%$44.44 - $52.3 $ 60.8224%119,600
George Soros 2017-03-31 Sold Out 0.27%$44.44 - $52.3 $ 60.8224%0
Richard Pzena 2017-03-31 Sold Out 0.06%$44.44 - $52.3 $ 60.8224%0
Bill Nygren 2016-12-31 New Buy1.34%$43.63 - $49.16 $ 60.8232%4,600,000
Vanguard Health Care Fund 2016-12-31 Reduce -36.89%0.18%$43.63 - $49.16 $ 60.8232%3,094,340
Tweedy Browne 2016-12-31 Reduce -0.30%0.01%$43.63 - $49.16 $ 60.8232%2,150,819
Joel Greenblatt 2016-12-31 Add 99.33%0.36%$43.63 - $49.16 $ 60.8232%1,271,879
Richard Pzena 2016-12-31 Reduce -78.73%0.24%$43.63 - $49.16 $ 60.8232%225,790
George Soros 2016-12-31 Reduce -27.52%0.12%$43.63 - $49.16 $ 60.8232%184,327
Mario Gabelli 2016-12-31 Reduce -2.11%$43.63 - $49.16 $ 60.8232%120,900
Keeley Asset Management Corp 2016-12-31 Reduce -62.60%0.08%$43.63 - $49.16 $ 60.8232%21,474
First Eagle Investment 2016-12-31 Reduce -99.96%0.32%$43.63 - $49.16 $ 60.8232%1,100
Vanguard Health Care Fund 2016-09-30 Reduce -30.49%0.21%$45.09 - $49.03 $ 60.8229%4,902,940
First Eagle Investment 2016-09-30 Add 23.75%0.06%$45.09 - $49.03 $ 60.8229%2,635,577
Tweedy Browne 2016-09-30 Reduce -9.87%0.3%$45.09 - $49.03 $ 60.8229%2,157,391
Richard Pzena 2016-09-30 Reduce -65.93%0.58%$45.09 - $49.03 $ 60.8229%1,061,577
Joel Greenblatt 2016-09-30 Reduce -24.86%0.11%$45.09 - $49.03 $ 60.8229%638,063
George Soros 2016-09-30 Reduce -10.55%0.04%$45.09 - $49.03 $ 60.8229%254,327
Mario Gabelli 2016-09-30 Reduce -1.28%$45.09 - $49.03 $ 60.8229%123,500
Keeley Asset Management Corp 2016-09-30 Reduce -2.05%$45.09 - $49.03 $ 60.8229%57,410
Leucadia National 2016-09-30 Sold Out 3.67%$45.09 - $49.03 $ 60.8229%0
Charles Brandes 2016-09-30 Sold Out 0.05%$45.09 - $49.03 $ 60.8229%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies    NAICS: 339112    SIC: 3841
Compare:NAS:ILMN, NYSE:BCR, NYSE:BDX, NYSE:MTD, NYSE:WAT, NAS:XRAY, NYSE:COO, NAS:HOLX, NYSE:RMD, NYSE:WST, NYSE:HRC, NAS:ICUI, NYSE:CMD, NAS:PODD, NYSE:HAE, NAS:MMSI, NYSE:HYH, NAS:NXTM, NYSE:GKOS, NAS:OSUR » details
Traded in other countries:BTL.Germany, BAX.Mexico, BAX.Switzerland, 0QK8.UK,
Headquarter Location:USA
Baxter International Inc operates in the healthcare industry. It provides renal and hospital products such as infusion systems and systems, parenteral nutrition therapies, and biosurgery products.

Baxter manufactures medical products across four major business segments. The renal segment (38% of sales) includes hemodialysis and peritoneal dialysis products. Integrated pharmacy solutions (23% of sales) includes nutrition, injectable drugs, and compounding services. IV pumps and solutions make up the fluid systems segment (21% of sales), while biosurgical supplies and anesthetic gases constitute the surgical care segment (13% of sales). Contract manufacturing services round out the roughly remaining 4% of sales.

Guru Investment Theses on Baxter International Inc

Daniel Loeb Comments on Baxter International - Jul 26, 2017

Two years ago, we initiated a 9.9% position worth over $1.5 billion in Baxter (NYSE:BAX). An under-earner in the medtech industry with margins trailing its peers, Baxter was about to spin out



its biopharma business, Baxalta. Shortly after the spin-off, Baxter’s long-time CEO announced his intention to retire. We believed these two major changes at the company presented an opportunity to create a more focused Baxter, cure its under-earning problem, and even make it an industry leader in operational performance – if the company took the right steps. Third Point’s Munib Islam joined the Baxter Board of Directors in September 2015. Munib also participated on the search committee that successfully recruited former Covidien CEO José “Joe” Almeida as Baxter’s new CEO starting on January 1, 2016.



Mr. Almeida’s sweeping changes to Baxter’s business over the past 18 months have created meaningful shareholder value. His tenure thus far is a case study on how leadership and cultural change can be transformational. Prior to his arrival, Baxter had guided to 2016 operating margins of 10%, growing to 14% by 2020. Under Mr. Almeida’s leadership, Baxter delivered 2016 operating margins of 13.6% and in May 2016, updated 2020 guidance to 17-18% operating margins. Due to continued strong operational performance, Baxter subsequently upgraded its 2020 guidance to ~20% operating margins on the Q2 2017 earnings call. The increases have been driven by multiple factors including:



  • Cost cutting initiatives: Mr. Almeida instituted a Zero-Base Budgeting process that had immediate impact: SG&A spend declined over 10% in 2016 vs pro forma 2015 levels, while R&D spend also declined year over year in absolute dollars.

  • Addition by subtraction: As part of an extensive portfolio review, Mr. Almeida madedecisionsto exitcertain unprofitable product lines/markets and legacy R&D projects with negative expected value.

  • Focus on high gross margin businesses: Baxter supplemented its generic injectable drug pipelinethrough three transactions and strategic partnerships (including the proposed acquisition of Claris Injectables). As the pipeline matures and products are approved, the high gross margin products will naturally improve Baxter’s underlying operating margin.

Baxter’s free cash flow generation has benefited from the improved operational efficiency. The prior free cash flow guidance was for $400 million in 2016 growing to $1.1 billion by 2020. Under Mr. Almeida, Baxter reported $ 935 million in 2016 free cash flow that is forecast to grow to ~$2.0 billion by 2020. Through the Zero-Base Budgeting process, the company has cut capex spending by nearly $200 million to $720 million in 2016 and forecasts continued reduction in capex through 2020.



In addition to continued margin expansion and improving free cash flow generation, there is renewed anticipation about how Baxter might deploy its pristine balance sheet. Since the spinoff, Baxter successfully monetized its Baxalta retained stake and currently sits at a zero net debt position; this contrasts with medtech peers who carry 1-2 turns of net leverage. Mr. Almeida has significant capacity to create value for shareholders through a combination of business development, share repurchases, and potential dividend increases.



Investors have clearly approved of Mr. Almeida and Baxter’s improved performance. Between January 1, 2016 and June 30, 2017, Baxter delivered a Total Shareholder Return (TSR) of 61%, nearly 3x the S&P 500 return of 22.4%. Despite the 18 month outperformance, Baxter’s forward EV / EBITDA multiple has remained largely unchanged at 12.5-13.0x; stock appreciation has been driven almost exclusively by an increase in Baxter’s underlying earnings power. Looking forward, we are confident that Mr. Almeida can combine operational efficiency with an unlevered balance sheet to drive continued earnings growth which – even absent any multiple expansion – should drive strong returns for Baxter shareholders.



From Dan Loeb's second quarter 2017 shareholder letter.



Check out Daniel Loeb latest stock trades

Daniel Loeb Comments on Baxter International - Jul 26, 2017

Two years ago, we initiated a 9.9% position worth over $1.5 billion in Baxter (NYSE:BAX). An under-earner in the medtech industry with margins trailing its peers, Baxter was about to spin out



its biopharma business, Baxalta. Shortly after the spin-off, Baxter’s long-time CEO announced his intention to retire. We believed these two major changes at the company presented an opportunity to create a more focused Baxter, cure its under-earning problem, and even make it an industry leader in operational performance – if the company took the right steps. Third Point’s Munib Islam joined the Baxter Board of Directors in September 2015. Munib also participated on the search committee that successfully recruited former Covidien CEO José “Joe” Almeida as Baxter’s new CEO starting on January 1, 2016.



Mr. Almeida’s sweeping changes to Baxter’s business over the past 18 months have created meaningful shareholder value. His tenure thus far is a case study on how leadership and cultural change can be transformational. Prior to his arrival, Baxter had guided to 2016 operating margins of 10%, growing to 14% by 2020. Under Mr. Almeida’s leadership, Baxter delivered 2016 operating margins of 13.6% and in May 2016, updated 2020 guidance to 17-18% operating margins. Due to continued strong operational performance, Baxter subsequently upgraded its 2020 guidance to ~20% operating margins on the Q2 2017 earnings call. The increases have been driven by multiple factors including:



  • Cost cutting initiatives: Mr. Almeida instituted a Zero-Base Budgeting process that had immediate impact: SG&A spend declined over 10% in 2016 vs pro forma 2015 levels, while R&D spend also declined year over year in absolute dollars.

  • Addition by subtraction: As part of an extensive portfolio review, Mr. Almeida madedecisionsto exitcertain unprofitable product lines/markets and legacy R&D projects with negative expected value.

  • Focus on high gross margin businesses: Baxter supplemented its generic injectable drug pipelinethrough three transactions and strategic partnerships (including the proposed acquisition of Claris Injectables). As the pipeline matures and products are approved, the high gross margin products will naturally improve Baxter’s underlying operating margin.

Baxter’s free cash flow generation has benefited from the improved operational efficiency. The prior free cash flow guidance was for $400 million in 2016 growing to $1.1 billion by 2020. Under Mr. Almeida, Baxter reported $ 935 million in 2016 free cash flow that is forecast to grow to ~$2.0 billion by 2020. Through the Zero-Base Budgeting process, the company has cut capex spending by nearly $200 million to $720 million in 2016 and forecasts continued reduction in capex through 2020.



In addition to continued margin expansion and improving free cash flow generation, there is renewed anticipation about how Baxter might deploy its pristine balance sheet. Since the spinoff, Baxter successfully monetized its Baxalta retained stake and currently sits at a zero net debt position; this contrasts with medtech peers who carry 1-2 turns of net leverage. Mr. Almeida has significant capacity to create value for shareholders through a combination of business development, share repurchases, and potential dividend increases.



Investors have clearly approved of Mr. Almeida and Baxter’s improved performance. Between January 1, 2016 and June 30, 2017, Baxter delivered a Total Shareholder Return (TSR) of 61%, nearly 3x the S&P 500 return of 22.4%. Despite the 18 month outperformance, Baxter’s forward EV / EBITDA multiple has remained largely unchanged at 12.5-13.0x; stock appreciation has been driven almost exclusively by an increase in Baxter’s underlying earnings power. Looking forward, we are confident that Mr. Almeida can combine operational efficiency with an unlevered balance sheet to drive continued earnings growth which – even absent any multiple expansion – should drive strong returns for Baxter shareholders.



Check out Daniel Loeb latest stock trades

Bill Nygren Comments on Baxter - Jan 10, 2017

Baxter (NYSE:BAX) is a collection of disparate health care businesses, which include dialysis consumables, intravenous solutions and surgical sealants. These businesses represent what was left at Baxter following the spinoff of Baxalta in mid-2015. The businesses hadn’t been run optimally, and at the time of the spin were only producing 9% margins, which represents less than half of the levels we believe to be achievable. Baxter hired outsider Jose Almeida as CEO in late 2015. Oakmark Fund shareholders might fondly remember Almeida from his successful tenure as CEO of our long-time holding Covidien, where he fixed (and eventually sold) a collection of health care assets that had been spun out from Tyco International. We believe Almeida has the right skill set to improve Baxter’s margins and portfolio of assets, and that the company is selling at a large discount to intrinsic value.



From Bill Nygren (Trades, Portfolio)'s Oakmark Fund fourth quarter 2016 commentary.

Check out Bill Nygren latest stock trades

Top Ranked Articles about Baxter International Inc

Analysts Release New Ratings on Health Care Stocks Raymond James, Citigroup and Morgan Stanley evaluate health care companies
Analysts recently released new ratings on some health care companies. Read more...
CHF Solutions Commences Manufacturing Transition of Aquadex FlexFlow® System to its Minnesota Facility
Daniel Loeb Comments on Baxter International Guru stock highlight
Two years ago, we initiated a 9.9% position worth over $1.5 billion in Baxter (NYSE:BAX). An under-earner in the medtech industry with margins trailing its peers, Baxter was about to spin out Read more...
Daniel Loeb Comments on Baxter International Guru stock highlight
Two years ago, we initiated a 9.9% position worth over $1.5 billion in Baxter (NYSE:BAX). An under-earner in the medtech industry with margins trailing its peers, Baxter was about to spin out Read more...
Daniel Loeb’s Favorite Idea Spurs May Outperformance High-conviction top position is more than twice size of next biggest
Returns at value-influenced Daniel Loeb (Trades, Portfolio)’s Third Point Offshore Fund exceeded the broader market for the first five months of the year, helped by a sizable advance in his most concentrated long position, Baxter International (NYSE:BAX). Read more...
Daniel Loeb’s Value-Seeking Journey This guru investor has gone from being a brash activist to an observer of the really big picture
Over slightly more than two decades, Loeb’s Master Fund has returned average annual returns of 17.9%. Read more...
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter International, Inc. (BAX)
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter International, Inc. - BAX
Edwards Lifesciences Director Buys 3,000 Shares Company increased revenue and gross profits at a solid rate over the last 10 years
Kieran Gallahue, director of Edwards Lifesciences (NYSE:EW), purchased 3,000 shares of the company for $90.10 per share on Feb. 3 according to a Form 4 filing with the Securities and Exchange Commission. He now owns 9,042 shares of the company. Read more...
Steven Romick Spots Next Area of Investment Interest: Health Care Romick has third of portfolio in cash, awaiting opportunities
At the $33.1 billion FPA Crescent Fund, widely followed stock manager Steven Romick (Trades, Portfolio) puts avoiding risk first, but he also embraces volatile markets to make steely buys of plummeting equities. Read more...

Ratios

vs
industry
vs
history
PE Ratio 36.42
BAX's PE Ratio is ranked higher than
77% of the 124 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. BAX: 36.42 )
Ranked among companies with meaningful PE Ratio only.
BAX' s PE Ratio Range Over the Past 10 Years
Min: 4.88  Med: 9.44 Max: 37.53
Current: 36.42
4.88
37.53
Forward PE Ratio 25.64
BAX's Forward PE Ratio is ranked higher than
50% of the 38 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.25 vs. BAX: 25.64 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 36.64
BAX's PE Ratio without NRI is ranked higher than
76% of the 123 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 30.55 vs. BAX: 36.64 )
Ranked among companies with meaningful PE Ratio without NRI only.
BAX' s PE Ratio without NRI Range Over the Past 10 Years
Min: 4.89  Med: 10.09 Max: 115.67
Current: 36.64
4.89
115.67
Price-to-Owner-Earnings 43.76
BAX's Price-to-Owner-Earnings is ranked higher than
76% of the 83 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 32.16 vs. BAX: 43.76 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
BAX' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 5.31  Med: 11.73 Max: 45.09
Current: 43.76
5.31
45.09
PB Ratio 3.60
BAX's PB Ratio is ranked lower than
57% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.29 vs. BAX: 3.60 )
Ranked among companies with meaningful PB Ratio only.
BAX' s PB Ratio Range Over the Past 10 Years
Min: 2.06  Med: 2.67 Max: 3.71
Current: 3.6
2.06
3.71
PS Ratio 3.26
BAX's PS Ratio is ranked higher than
50% of the 185 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.24 vs. BAX: 3.26 )
Ranked among companies with meaningful PS Ratio only.
BAX' s PS Ratio Range Over the Past 10 Years
Min: 1.06  Med: 1.61 Max: 3.36
Current: 3.26
1.06
3.36
Price-to-Free-Cash-Flow 25.45
BAX's Price-to-Free-Cash-Flow is ranked higher than
69% of the 70 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 27.92 vs. BAX: 25.45 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
BAX' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 6.94  Med: 10.08 Max: 54.26
Current: 25.45
6.94
54.26
Price-to-Operating-Cash-Flow 17.07
BAX's Price-to-Operating-Cash-Flow is ranked higher than
68% of the 91 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.25 vs. BAX: 17.07 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
BAX' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 4.57  Med: 7.22 Max: 19.32
Current: 17.07
4.57
19.32
EV-to-EBIT 29.21
BAX's EV-to-EBIT is ranked higher than
68% of the 119 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 23.41 vs. BAX: 29.21 )
Ranked among companies with meaningful EV-to-EBIT only.
BAX' s EV-to-EBIT Range Over the Past 10 Years
Min: -2940.9  Med: 8.5 Max: 63.8
Current: 29.21
-2940.9
63.8
EV-to-EBITDA 17.20
BAX's EV-to-EBITDA is ranked higher than
73% of the 133 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 18.62 vs. BAX: 17.20 )
Ranked among companies with meaningful EV-to-EBITDA only.
BAX' s EV-to-EBITDA Range Over the Past 10 Years
Min: 4.1  Med: 6.8 Max: 45.7
Current: 17.2
4.1
45.7
Shiller PE Ratio 14.37
BAX's Shiller PE Ratio is ranked higher than
92% of the 49 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 50.16 vs. BAX: 14.37 )
Ranked among companies with meaningful Shiller PE Ratio only.
BAX' s Shiller PE Ratio Range Over the Past 10 Years
Min: 9.7  Med: 12.84 Max: 21.84
Current: 14.37
9.7
21.84
Current Ratio 3.01
BAX's Current Ratio is ranked higher than
52% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.69 vs. BAX: 3.01 )
Ranked among companies with meaningful Current Ratio only.
BAX' s Current Ratio Range Over the Past 10 Years
Min: 1.08  Med: 1.65 Max: 3.01
Current: 3.01
1.08
3.01
Quick Ratio 2.42
BAX's Quick Ratio is ranked higher than
58% of the 189 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.74 vs. BAX: 2.42 )
Ranked among companies with meaningful Quick Ratio only.
BAX' s Quick Ratio Range Over the Past 10 Years
Min: 0.74  Med: 1.06 Max: 2.42
Current: 2.42
0.74
2.42
Days Inventory 93.36
BAX's Days Inventory is ranked higher than
70% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 127.43 vs. BAX: 93.36 )
Ranked among companies with meaningful Days Inventory only.
BAX' s Days Inventory Range Over the Past 10 Years
Min: 91.48  Med: 138.8 Max: 219.03
Current: 93.36
91.48
219.03
Days Sales Outstanding 61.09
BAX's Days Sales Outstanding is ranked higher than
53% of the 158 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 61.12 vs. BAX: 61.09 )
Ranked among companies with meaningful Days Sales Outstanding only.
BAX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 58.53  Med: 66.28 Max: 112.88
Current: 61.09
58.53
112.88

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield % 0.90
BAX's Dividend Yield % is ranked lower than
58% of the 159 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.17 vs. BAX: 0.90 )
Ranked among companies with meaningful Dividend Yield % only.
BAX' s Dividend Yield % Range Over the Past 10 Years
Min: 0.88  Med: 3.82 Max: 5.89
Current: 0.9
0.88
5.89
Dividend Payout Ratio 0.33
BAX's Dividend Payout Ratio is ranked higher than
96% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.30 vs. BAX: 0.33 )
Ranked among companies with meaningful Dividend Payout Ratio only.
BAX' s Dividend Payout Ratio Range Over the Past 10 Years
Min: 0.06  Med: 0.35 Max: 3.37
Current: 0.33
0.06
3.37
3-Year Dividend Growth Rate -35.90
BAX's 3-Year Dividend Growth Rate is ranked lower than
89% of the 63 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 8.40 vs. BAX: -35.90 )
Ranked among companies with meaningful 3-Year Dividend Growth Rate only.
BAX' s 3-Year Dividend Growth Rate Range Over the Past 10 Years
Min: -35.9  Med: 6.3 Max: 22.5
Current: -35.9
-35.9
22.5
Forward Dividend Yield % 1.05
BAX's Forward Dividend Yield % is ranked lower than
63% of the 145 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.35 vs. BAX: 1.05 )
Ranked among companies with meaningful Forward Dividend Yield % only.
N/A
5-Year Yield-on-Cost % 0.43
BAX's 5-Year Yield-on-Cost % is ranked lower than
66% of the 186 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.44 vs. BAX: 0.43 )
Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
BAX' s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.42  Med: 1.83 Max: 2.82
Current: 0.43
0.42
2.82
3-Year Average Share Buyback Ratio 0.20
BAX's 3-Year Average Share Buyback Ratio is ranked higher than
86% of the 128 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -4.00 vs. BAX: 0.20 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BAX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -5.1  Med: -0.4 Max: 3.3
Current: 0.2
-5.1
3.3

Valuation & Return

vs
industry
vs
history
Price-to-Tangible-Book 6.22
BAX's Price-to-Tangible-Book is ranked lower than
64% of the 155 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 4.71 vs. BAX: 6.22 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
BAX' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 2.11  Med: 5.07 Max: 18.21
Current: 6.22
2.11
18.21
Price-to-Intrinsic-Value-Projected-FCF 1.44
BAX's Price-to-Intrinsic-Value-Projected-FCF is ranked higher than
74% of the 86 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.25 vs. BAX: 1.44 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
BAX' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 0.52  Med: 1.02 Max: 2.71
Current: 1.44
0.52
2.71
Price-to-Median-PS-Value 2.03
BAX's Price-to-Median-PS-Value is ranked lower than
87% of the 171 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.12 vs. BAX: 2.03 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BAX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.19  Med: 0.82 Max: 2.11
Current: 2.03
0.19
2.11
Price-to-Graham-Number 3.18
BAX's Price-to-Graham-Number is ranked higher than
55% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. BAX: 3.18 )
Ranked among companies with meaningful Price-to-Graham-Number only.
BAX' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 0.76  Med: 1.53 Max: 7
Current: 3.18
0.76
7
Earnings Yield (Greenblatt) % 3.42
BAX's Earnings Yield (Greenblatt) % is ranked higher than
80% of the 192 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.70 vs. BAX: 3.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BAX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 1.6  Med: 11.6 Max: 20.9
Current: 3.42
1.6
20.9
Forward Rate of Return (Yacktman) % 7.23
BAX's Forward Rate of Return (Yacktman) % is ranked lower than
59% of the 94 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.23 vs. BAX: 7.23 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BAX' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -11.8  Med: 15.7 Max: 30
Current: 7.23
-11.8
30

More Statistics

Revenue (TTM) (Mil) $10,283.00
EPS (TTM) $ 1.67
Beta0.80
Short Percentage of Float1.11%
52-Week Range $43.13 - 63.14
Shares Outstanding (Mil)544.87

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 10,464 10,905 11,415
EPS ($) 2.34 2.63 2.95
EPS without NRI ($) 2.34 2.63 2.95
EPS Growth Rate
(Future 3Y To 5Y Estimate)
14.82%
Dividends per Share ($) 0.61 0.66 0.77
» More Articles for BAX

Headlines

Articles On GuruFocus.com
CHF Solutions Commences Manufacturing Transition of Aquadex FlexFlow® System to its Minnesota Fa Aug 03 2017 
6 Stocks Beating the Market Jul 31 2017 
Daniel Loeb Comments on Baxter International Jul 26 2017 
Daniel Loeb Comments on Baxter International Jul 26 2017 
Daniel Loeb Discusses Baxter, Alibaba in Q2 Letter Jul 26 2017 
Daniel Loeb’s Favorite Idea Spurs May Outperformance Jun 05 2017 
5 Companies Reach Yearly Highs May 03 2017 
Daniel Loeb’s Value-Seeking Journey Apr 30 2017 
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Baxter Internationa Apr 19 2017 
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Baxter Internati Apr 17 2017 

More From Other Websites
Baxter International, Inc. – Value Analysis (NYSE:BAX) : August 16, 2017 Aug 16 2017
Baxter International, Inc. breached its 50 day moving average in a Bullish Manner : BAX-US : August... Aug 16 2017
Baxter to Present at the Goldman Sachs 14th Annual European Medtech and Healthcare Services... Aug 15 2017
See what the IHS Markit Score report has to say about Baxter International Inc. Aug 14 2017
Edited Transcript of BAX earnings conference call or presentation 26-Jul-17 12:30pm GMT Aug 12 2017
Baxter International, Inc. breached its 50 day moving average in a Bearish Manner : BAX-US : August... Aug 03 2017
CHF Solutions Commences Manufacturing Transition of Aquadex FlexFlow® System to its Minnesota... Aug 03 2017
Baxter International, Becton Dickinson, Boston Scientific: Cramer's Top Takeaways Aug 01 2017
Cramer Remix: 3 red-hot stocks ready to roar higher Jul 31 2017
Zacks.com featured highlights: Baxter International, Coca-Cola FEMSA, S.A.B. de C.V., Banco Bilbao... Jul 31 2017
Bet on These 5 GARP Stocks with Discounted PEG Ratio Jul 28 2017
Corporate News Blog - Sensus Healthcare Announces Achievement of Approval from China's FDA for... Jul 28 2017
Baxter International Inc.'s Revenue Growth Snoozes, but Check Out the Earnings Growth Jul 27 2017
Baxter Completes Acquisition of Claris Injectables, Expanding Generic Injectable Medicines Portfolio Jul 27 2017
Baxter beats Street 2Q forecasts Jul 26 2017
Daniel Loeb Discusses Baxter, Alibaba in Q2 Letter Jul 26 2017
Highlights From Third Point's Q2 Investor Letter: Baxter, Alibaba and BlackRock Jul 26 2017
Baxter (BAX) Beats on Q2 Earnings, Raises Long-Term Outlook Jul 26 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}